Summary of findings for cholinesterase inhibitors vs placebo
Number of people sustaining one or more fall‐related fractures · people with Parkinson's disease
1 finding from 1 review
- no estimate extracted1 study · 23 participantsVery low
Findings
What do systematic reviews say?
1,166 questions · 1,249 findings · 76 reviews
No studies found 378 · 30.3%GRADE not reported 61 · 4.9%Very low 377 · 30.2%Low 284 · 22.7%Moderate 120 · 9.6%High 29 · 2.3%
Low molecular weight heparin vs placebo or no treatment
Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyRR 0.27 [0.06, 1.18]1 study · 45 participantsVery low
Low molecular weight heparin vs placebo or no treatment
Overall survival · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs placebo or no treatment
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs placebo or no treatment
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs placebo or no treatment
Quality of life · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs placebo or no treatment
Frequency of adverse events ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyRR 0.74 [0.27, 2]1 study · 61 participantsVery low
Low molecular weight heparin vs prostaglandin E1
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyRR 0.61 [0.24, 1.55]1 study · 93 participantsVery low
Low molecular weight heparin vs prostaglandin E1
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs prostaglandin E1
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs prostaglandin E1
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyRR 0.2 [0.01, 4.14]1 study · 93 participantsVery low
Low molecular weight heparin vs prostaglandin E1
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs prostaglandin E1
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
- Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes onlyRR 0.51 [0.23, 1.15]1 study · 93 participantsVery low
Summary of findings for spaced retrieval training programme for people with dementia vs no intervention
Food and fluid intake, measured as amount of served food eaten (percentage, · people with dementia
1 finding from 1 review
- Environmental and behavioural modifications for improving food and fluid intake in people with dementia 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 54 participantsVery low
Summary of findings for spaced retrieval training programme for people with dementia vs no intervention
Nutritional status · people with dementia
2 findings from 1 review
- Environmental and behavioural modifications for improving food and fluid intake in people with dementia 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 54 participantsVery low
- Environmental and behavioural modifications for improving food and fluid intake in people with dementia 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 33 participantsVery low
Summary of findings for spaced retrieval training programme for people with dementia vs no intervention
Nutritional status, measured by body weight (kg, · people with dementia
1 finding from 1 review
- Environmental and behavioural modifications for improving food and fluid intake in people with dementia 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 33 participantsVery low
Summary of findings for spaced retrieval training programme for people with dementia vs no intervention
Mealtime behaviour · people with dementia
1 finding from 1 review
- Environmental and behavioural modifications for improving food and fluid intake in people with dementia 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 54 participantsVery low
Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes
Time taken from start of treatment until the resolution of DIOS · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes
Treatment failure rate · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes
Adherence · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found